DuRoss Amy sold (to issuer) 26,857 shares of BLFS

DuRoss Amy sold (to issuer) 26,857 shares of BIOLIFE SOLUTIONS INC (BLFS) on 2026-10-06.

Original reporting
SEC EDGAR · DuRoss Amy
Published Oct 9, 2026, 1:59 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 9, 2026, 2:02 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$BLFS
Bearish
medium confidence
Mentioned
$BLFS
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BLFSBearishLow
01

Why it matters

The director's complete exit may be interpreted as a negative signal, but the modest share count limits market reaction.

02

Market read

A small insider sale with no disclosed price, likely causing limited short-term price movement.

03

What to watch

No price disclosed; the market may not react significantly without valuation context.

Relevance 4/10Novelty 4/10Timing: filing today

Background

Form 4 filings disclose insider transactions to the SEC, providing transparency on insider activity.

Company-level read

Ticker impact

$BLFSBearishMedium confidence
Context

Director Amy DuRoss sold her entire holding of 26,857 shares of Biolife Solutions in a Form 4 filing.

Expected impact

potential slight downward pressure

Evidence & confidence

A director disposing of all shares can be viewed as a negative signal, but the transaction size is modest.

Market effects

minimal impact on the biotech sector

limited effect on US markets

low global relevance

Counterpoint

The sale could be a routine portfolio rebalancing rather than a lack of confidence.

Key entities

  • Biolife Solutions Inc

    US-listed biotech firm (ticker BLFS) whose director sold shares.

  • Amy DuRoss

    Director of Biolife Solutions who filed the Form 4.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$RGENHighAI 8/10

REPLIGEN CORP (RGEN): Completion of Acquisition or Disposition of Assets

REPLIGEN CORP (RGEN) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 REPLIGEN COMPLETES ACQUISITION OF BIOLIFE SOLUTIONS WALTHAM, MA - October 6, 2026 – Repligen Corporation (NASDAQ: RGEN, “Repligen”, or the “Company”), a life sciences company foc

$RGENHigh

BIOLIFE SOLUTIONS INC (BLFS): Completion of Acquisition or Disposition of Assets

BIOLIFE SOLUTIONS INC (BLFS) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Item 2.01 Completion of Acquisition or Disposition of Assets. The information set forth in the “Explanatory Note” of this Current Report on Form 8-K is incorporated by reference into this Item 2.01. At the effective time of the First Merger (the “First Merger Effective Time”), ea

$RGENHighAI 8/10

Repligen Completes Acquisition of BioLife Solutions

Repligen Corporation (NASDAQ: RGEN) completed its acquisition of BioLife Solutions (NASDAQ: BLFS) for $11.25 per share in cash and 0.1442 shares of Repligen stock. The deal expands Repligen's presence in the cell therapy market, adding high-margin consumables and recurring revenue. BioLife's products support 18 approved therapies and most U.S. cell-based therapy trials. Repligen will discuss the transaction's financial impact on its Q3 2026 earnings call.

$FRSHHighAI 8/10

Freshworks to Replace BioLife Solutions in S&P SmallCap 600

S&P Dow Jones Indices announced Freshworks (FRSH) will replace BioLife Solutions (BLFS) in the S&P SmallCap 600 on October 8, 2026. Repligen (RGN) is acquiring BioLife for $1.5B, with BioLife shareholders receiving $11.25 per share in cash and 0.1442 shares of Repligen stock. Freshworks reported Q2 2026 revenue of $237.4M, up 16% YoY, and its first GAAP profitability in 2026.